$0.314
+0.022 (+6.91%)收盘时
AEON 同业对比
In the context of the broader market, AEON competes directly with industry leaders such as HIND and NRSN. With a market capitalization of $15.67M, it holds a significant position in the sector. When comparing efficiency, AEON's gross margin of N/A stands against HIND's 33.57% and NRSN's N/A. Such benchmarking helps identify whether Aeon Biopharma Inc is trading at a premium or discount relative to its financial performance.
Aeon Biopharma Inc 财务表现
Aeon Biopharma has shown a volatile financial performance with significant net losses, including -11,793,000 USD in Q1 2026 and a forward P/E of 1.1577, indicating potential for future earnings growth if the company can stabilize.
Financials
FY2026Q2
YoY:
+37.18%
-5.93M
Operating Profit
FY2026Q2
YoY:
-82.61%
-1.16M
Net Income after Tax
FY2026Q2
YoY:
-96.67%
-0.02
EPS - Diluted
FY2026Q1
YoY:
-66.69%
-2.64M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。